Top

Published in:

01-05-2018 | Original Article

CD19 targeted CAR-T therapy versus chemotherapy in re-induction treatment of refractory/relapsed acute lymphoblastic leukemia: results of a case-controlled study

Authors: Guoqing Wei, Yongxian Hu, Chengfei Pu, Jian Yu, Yi Luo, Jimin Shi, Qu Cui, Wenjun Wu, Jinping Wang, Lei Xiao, Zhao Wu, He Huang

Published in: Annals of Hematology | Issue 5/2018

Abstract

Chimeric antigen receptor modified T cells against CD19 (CART19s) have potent anti-leukemia activities in patients with refractory/relapsed acute lymphoblastic leukemia (R/R ALL). This study was designed to investigate the correlation between safety/efficacy and therapeutic modalities including chemotherapy and CART19 therapy. Total 23 and 69 patients were enrolled in the CART19 group and in the chemotherapy group, respectively. The safety and efficacy profiles of 66 and 22 patients in the 2 groups were evaluated. The complete remission (CR) rate was higher in the CART19 group than that in the chemotherapy group (90.9 vs 37.9%, P = 0.000). For patients relapsed after allo-HSCT and chemotherapy, CR rates were 100% (8/8) vs 48.0% (12/25) (P = 0.009) and 85.7% (12/14) vs 31.7% (13/41) (P = 0.000), respectively. Moreover, a higher percentage in the CART19 group had results below the threshold for minimal residual disease (100 vs 7.58%, P = 0.000). In survival analysis, the overall survival rate at 12 months was higher in the CART19 group than that in the chemotherapy group (60.9 vs 10.1%, P = 0.000). For post-transplant patients achieving CR, 25.0% (2/8) and 75.0% (9/12) complicated with GVHD (P = 0.04) in the CART19 group and chemotherapy group, respectively. For all CR patients, the median duration of absolute neutrophil count less than 500/μL and platelet count less than 20,000/μL were longer in the CART19 group than in the chemotherapy group (p = 0.0047 and 0.0003, respectively). Our data demonstrated that patients with CART19s therapy acquired higher rates of remission and longer survival, confirming the encouraging application of CART19 therapy in R/R ALL.

Available only for authorised users

Kantarjian H, Stein A, Gökbuget N, Fielding AK, Schuh AC, Ribera JM, Wei A, Dombret H, Foà R, Bassan R, Arslan Ö, Sanz MA, Bergeron J, Demirkan F, Lech-Maranda E, Rambaldi A, Thomas X, Horst HA, Brüggemann M, Klapper W, Wood BL, Fleishman A, Nagorsen D, Holland C, Zimmerman Z, Topp MS (2017) Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med 376(9):836–847. https://doi.org/10.1056/NEJMoa1609783 CrossRefPubMed

Gökbuget N, Kelsh M, Chia V, Advani A, Bassan R, Dombret H, Doubek M, Fielding AK, Giebel S, Haddad V, Hoelzer D, Holland C, Ifrah N, Katz A, Maniar T, Martinelli G, Morgades M, O'Brien S, Ribera JM, Rowe JM, Stein A, Topp M, Wadleigh M, Kantarjian H (2016) Blinatumomab vs historical standard therapy of adult relapsed/refractory acute lymphoblastic leukemia. Blood Cancer J 6(9):e473. https://doi.org/10.1038/bcj.2016.84 CrossRefPubMedPubMedCentral

Gökbuget N, Dombret H, Ribera JM, Fielding AK, Advani A, Bassan R et al (2016) International reference analysis of outcomes in adults with B-precursor Ph-negative relapsed/refractory acute lymphoblastic leukemia. Haematologica 101(12):1524–1533. https://doi.org/10.3324/haematol.2016.144311 CrossRefPubMedPubMedCentral

Stein A, Palmer J, Tsai NC, Al Malki MM, Aldoss I, Ali H, Aribi A, Farol L, Karanes C, Khaled S, Liu A, O'Donnell M, Parker P, Pawlowska A, Pullarkat V, Radany E, Rosenthal J, Sahebi F, Salhotra A, Sanchez JF, Schultheiss T, Spielberger R, Thomas SH, Snyder D, Nakamura R, Marcucci G, Forman SJ, Wong J (2017) Phase I trial of total marrow and lymphoid irradiation transplantation conditioning in patients with relapsed/refractory acute leukemia. Biol Blood Marrow Transplant 23(4):618–624. https://doi.org/10.1016/j.bbmt.2017.01.067 CrossRefPubMed

Jabbour E, Short NJ, Jorgensen JL, Yilmaz M, Ravandi F, Wang SA, Thomas DA, Khoury J, Champlin RE, Khouri I, Kebriaei P, O'Brien SM, Garcia-Manero G, Cortes JE, Sasaki K, Dinardo CD, Kadia TM, Jain N, Konopleva M, Garris R, Kantarjian HM (2017) Differential impact of minimal residual disease negativity according to the salvage status in patients with relapsed/refractory B-cell acute lymphoblastic leukemia. Cancer 123(2):294–302. https://doi.org/10.1002/cncr.30264 CrossRefPubMed

Oriol A, Vives S, Hernández-Rivas JM et al (2010) Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. Haematologica 95(4):589–596. https://doi.org/10.3324/haematol.2009.014274 CrossRefPubMedPubMedCentral

Haen SP, Groh C, Schumm M, Backert L, Löffler MW, Federmann B, Faul C, Dörfel D, Vogel W, Handgretinger R, Kanz L, Bethge WA (2017) Haploidentical hematopoietic cell transplantation using in vitro T cell depleted grafts as salvage therapy in patients with disease relapse after prior allogeneic transplantation. Ann Hematol 96(5):817–827. https://doi.org/10.1007/s00277-017-2941-x CrossRefPubMed

Yoo SH, Koh Y, Kim DY, Lee JH, Lee JH, Lee KH, Korean Society of Blood and Marrow Transplantation et al (2017) Salvage therapy for acute chemorefractory leukemia by allogeneic stem cell transplantation: the Korean experience. Ann Hematol 96(4):605–615. https://doi.org/10.1007/s00277-017-2919-8 CrossRefPubMed

DasGupta RK, Marini BL, Rudoni J, Perissinotti AJ (2017) A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia. J Oncol Pharm Pract 1078155217713363:107815521771336. https://doi.org/10.1177/1078155217713363 CrossRef

10.

Hay KA, Turtle CJ (2017) Chimeric antigen receptor (CAR) T cells: lessons learned from targeting of CD19 in B-cell malignancies. Drugs 77(3):237–245. https://doi.org/10.1007/s40265-017-0690-8 CrossRefPubMedPubMedCentral

11.

Hu Y, Wu Z, Luo Y, Shi J, Yu J, Pu C, Liang Z, Wei G, Cui Q, Sun J, Jiang J, Xie J, Tan Y, Ni W, Tu J, Wang J, Jin A, Zhang H, Cai Z, Xiao L, Huang H (2017) Potent anti-leukemia activities of chimeric antigen receptor-modified T cells against CD19 in Chinese patients with relapsed/refractory acute lymphocytic leukemia. Clin Cancer Res 23(13):3297–3306. https://doi.org/10.1158/1078-0432.CCR-16-1799 CrossRefPubMed

12.

Hu Y, Sun J, Wu Z, Yu J, Cui Q, Pu C, Liang B, Luo Y, Shi J, Jin A, Xiao L, Huang H (2016) Predominant cerebral cytokine release syndrome in CD19-directed chimeric antigen receptor-modified T cell therapy. J Hematol Oncol 9(1):70. https://doi.org/10.1186/s13045-016-0299-5 CrossRefPubMedPubMedCentral

13.

Tan Y, Du K, Luo Y, Shi J, Cao L, Zheng Y, Zheng G, Zhao Y, Ye X, Cai Z, Huang H (2014) Superiority of preemptive donor lymphocyte infusion based on minimal residual disease in acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Transfusion 54(6):1493–1500. https://doi.org/10.1111/trf.12524 CrossRefPubMed

14.

Lee DW, Kochenderfer JN, Stetler-Stevenson M, Cui YK, Delbrook C, Feldman SA, Fry TJ, Orentas R, Sabatino M, Shah NN, Steinberg SM, Stroncek D, Tschernia N, Yuan C, Zhang H, Zhang L, Rosenberg SA, Wayne AS, Mackall CL (2015) T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 dose-escalation trial. Lancet 385(9967):517–528. https://doi.org/10.1016/S0140-6736(14)61403-3 CrossRefPubMed

15.

Valecha GK, Ibrahim U, Ghanem S, Asti D, Atallah JP, Terjanian T (2017) Emerging role of immunotherapy in precursor B-cell acute lymphoblastic leukemia. Expert Rev Hematol 10:1–17. https://doi.org/10.1080/17474086 CrossRef

16.

Maude SL, Frey N, Shaw PA, Aplenc R, Barrett DM, Bunin NJ, Chew A, Gonzalez VE, Zheng Z, Lacey SF, Mahnke YD, Melenhorst JJ, Rheingold SR, Shen A, Teachey DT, Levine BL, June CH, Porter DL, Grupp SA (2014) Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 371(16):1507–1517. https://doi.org/10.1056/NEJMoa1407222 CrossRefPubMedPubMedCentral

17.

Davila ML, Riviere I, Wang X, Bartido S, Park J, Curran K, Chung SS et al (2014) Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 6:224ra25.1CrossRef

18.

Dai H, Wang Y, Lu X, Han W (2016) Chimeric antigen receptors modified T-cells for cancer therapy. J Natl Cancer Inst 108(7). https://doi.org/10.1093/jnci/djv439

19.

Eichhorst B, Fink AM, Bahlo J, Busch R, Kovacs G, Maurer C, Lange E, Köppler H, Kiehl M, Sökler M, Schlag R, Vehling-Kaiser U, Köchling G, Plöger C, Gregor M, Plesner T, Trneny M, Fischer K, Döhner H, Kneba M, Wendtner CM, Klapper W, Kreuzer KA, Stilgenbauer S, Böttcher S, Hallek M, international group of investigators; German CLL Study Group (GCLLSG) (2016) First-line chemoimmunotherapy with bendamustine and rituximab versus fludarabine, cyclophosphamide, and rituximab in patients with advanced chronic lymphocytic leukaemia (CLL10): an international, open-label, randomised, phase 3, non-inferiority trial. Lancet Oncol 17(7):928–942. https://doi.org/10.1016/S1470-2045(16)30051-1 CrossRefPubMed

20.

Skarbnik AP, Faderl S (2017) The role of combined fludarabine, cyclophosphamide and rituximab chemoimmunotherapy in chronic lymphocytic leukemia: current evidence and controversies. Ther Adv Hematol 8(3):99–105. https://doi.org/10.1177/2040620716681749 CrossRefPubMed

21.

Mauro FR, Carella AM, Molica S, Paoloni F, Liberati AM, Zaja F, Belsito V, Cortellezzi A, Rizzi R, Tosi P, Spriano M, Ferretti A, Nanni M, Marinelli M, de Propris MS, Orlando SM, Vignetti M, Cuneo A, Guarini AR, Foà R (2017) Fludarabine, cyclophosphamide and lenalidomide in patients with relapsed/refractory chronic lymphocytic leukemia. A multicenter phase I-II GIMEMA trial. Leuk Lymphoma 58(7):1640–1647. https://doi.org/10.1080/10428194.2016.1258698 CrossRefPubMed

22.

Canna SW, Wrobel J, Chu N, Kreiger PA, Paessler M, Behrens EM (2013) Interferon-γ mediates anemia but is dispensable for fulminant toll-like receptor 9-induced macrophage activation syndrome and hemophagocytosis in mice. Arthritis Rheum 65(7):1764–1775. https://doi.org/10.1002/art.37958 CrossRefPubMedPubMedCentral

23.

Chen J, Feng X, Desierto MJ, Keyvanfar K, Young NS (2015) IFN-γ-mediated hematopoietic cell destruction in murine models of immune-mediated bone marrow failure. Blood 126(24):2621–2631. https://doi.org/10.1182/blood-2015-06-652453 CrossRefPubMedPubMedCentral

24.

Smith JN, Kanwar VS, MacNamara KC (2016) Hematopoietic stem cell regulation by type I and II interferons in the pathogenesis of acquired aplastic anemia. Front Immunol 7:330PubMedPubMedCentral

25.

DeAngelo DJ, Stock W, Stein AS, Shustov A, Liedtke M, Schiffer CA, Vandendries E, Liau K, Ananthakrishnan R, Boni J, Laird AD, Fostvedt L, Kantarjian HM, Advani AS (2017) Inotuzumab ozogamicin in adults with relapsed or refractory CD22-positive acute lymphoblastic leukemia: a phase 1/2 study. Blood Adv 1(15):1167–1180. https://doi.org/10.1182/bloodadvances.2016001925 CrossRefPubMedPubMedCentral

26.

Topp MS, Gokbuget N, Stein AS, Zugmaier G, O'Brien S, Bargou RC et al (2015) Safety and activity of blinatumomab for adult patients with relapsed or refractory B-precursor acute lymphoblastic leukaemia: a multicentre, single-arm, phase 2 study. Lancet Oncol 16:57e66CrossRef

27.

Frey N (2017) Cytokine release syndrome: who is at risk and how to treat. Best Pract Res Clin Haematol 30(4):336–340. https://doi.org/10.1016/j.beha.2017.09.002 CrossRefPubMed

Title: CD19 targeted CAR-T therapy versus chemotherapy in re-induction treatment of refractory/relapsed acute lymphoblastic leukemia: results of a case-controlled study
Authors: Guoqing Wei
Yongxian Hu
Chengfei Pu
Jian Yu
Yi Luo
Jimin Shi
Qu Cui
Wenjun Wu
Jinping Wang
Lei Xiao
Zhao Wu
He Huang
Publication date: 01-05-2018
Publisher: Springer Berlin Heidelberg
Published in: Annals of Hematology / Issue 5/2018
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI: https://doi.org/10.1007/s00277-018-3246-4

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

2024 ASCO Annual Meeting

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2018

A phase I–II study of plerixafor in combination with fludarabine, idarubicin, cytarabine, and G-CSF (PLERIFLAG regimen) for the treatment of patients with the first early-relapsed or refractory acute myeloid leukemia

Identification and assessment of frailty in older patients with chronic myeloid leukemia and myelofibrosis, and indications for tyrosine kinase inhibitor treatment

Combined PD-1 and JAK1/2 inhibition in refractory primary mediastinal B-cell lymphoma

Sleep-disordered breathing in patients with sickle cell disease

Salvage therapy post pomalidomide-based regimen in relapsed/refractory myeloma

Relapse of acute promyelocytic leukemia in the external auditory canal confirmed by PML/RARA dual-fusion and RARA break-apart fluorescence in situ hybridization

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials